HCPCS
J9263
1 unit = 0.5 mg
Phase 1
Identify what you're billing
Confirm the regimen, dose, BSA, and unit basis before billing.
Combination regimens that include oxaliplatin NCCN v2.2026 verified May 2026
Oxaliplatin is almost never given as monotherapy. The regimen drives the cycle length, BSA dose, premedications, and combination admin codes.
| Regimen | Components | Oxaliplatin dose | Cycle | Primary indication |
|---|---|---|---|---|
| FOLFOX (mFOLFOX-6) | Oxaliplatin + leucovorin + 5-FU bolus + 5-FU 46-hr CIV | 85 mg/m² Day 1 | 14 days | 1L mCRC; adjuvant stage III CRC (12 cycles) |
| FOLFOXIRI | FOLFOX + irinotecan | 85 mg/m² Day 1 | 14 days | More aggressive 1L mCRC (good performance status) |
| CapeOx / XELOX | Oxaliplatin + oral capecitabine (no infusional 5-FU) | 130 mg/m² Day 1 | 21 days | 1L mCRC alternative to FOLFOX; adjuvant CRC |
| FOLFIRINOX | Oxaliplatin + irinotecan + leucovorin + 5-FU | 85 mg/m² Day 1 | 14 days | Pancreatic cancer (1L metastatic + adjuvant) |
| FLOT | Oxaliplatin + leucovorin + 5-FU + docetaxel | 85 mg/m² Day 1 | 14 days | Peri-operative gastric / GEJ / esophageal adenocarcinoma |
| FOLFOX + bevacizumab | FOLFOX + bevacizumab (J9035) | 85 mg/m² Day 1 | 14 days | 1L mCRC with VEGF-targeted therapy |
| FOLFOX + cetuximab/panitumumab | FOLFOX + EGFR antibody (KRAS/NRAS WT only) | 85 mg/m² Day 1 | 14 days | 1L left-sided mCRC, RAS WT |
| FOLFOX + pembrolizumab | FOLFOX + Keytruda (J9271) | 85 mg/m² Day 1 | 14 days (cycles align) | MSI-H/dMMR mCRC (some payer pathways) |
FOLFOX is the workhorse. 85 mg/m² q14d is the dose you'll see on most oxaliplatin
claims. Adjuvant stage III colon cancer (12 cycles) and 1L metastatic CRC are the high-volume
indications. CapeOx (130 mg/m² q21d) is the alternative when payers or patients prefer oral
capecitabine over an infusion pump.
Combination admin coding: oxaliplatin is typically the initial drug billed at
96413 (chemo IV first hour). Subsequent agents in the cycle (irinotecan, 5-FU bolus, etc.)
bill 96417 (each additional sequential infusion). The 5-FU 46-hour CIV through a portable
pump bills under 96416 (initiation of prolonged chemo infusion, requires use of portable
or implantable pump). Verify your charge capture has all sequential infusion codes for the full cycle.
Dosing & unit math FDA label verified May 2026
From the FDA prescribing information (Eloxatin originator + generic SPLs).
BSA-based dosing — the math that drives unit calculation
Oxaliplatin is dosed in milligrams per square meter of body surface area (mg/m²). Every patient gets a BSA-calculated dose, then milligrams are converted to J9263 units by multiplying by 2 (because 1 unit = 0.5 mg).
- FOLFOX / FOLFOXIRI / FOLFIRINOX / FLOT (q14d): 85 mg/m²
- CapeOx / XELOX (q21d): 130 mg/m²
- Round up to fill smallest combination of 50/100/200 mg vials
- Calculate waste (drawn dose − administered mg) and bill JW for waste in 0.5 mg units
BSA-to-units quick reference (85 mg/m² FOLFOX dose)
| BSA (m²) | Dose (mg) | Vials drawn | Total drug (mg) | Waste (mg) | JZ units | JW units |
|---|---|---|---|---|---|---|
| 1.5 | 128 | 1 × 100 + 1 × 50 = 150 | 150 | 22 | 256 | 44 |
| 1.7 | 145 | 1 × 100 + 1 × 50 = 150 | 150 | 5 | 290 | 10 |
| 1.85 | 157 | 2 × 100 = 200 | 200 | 43 | 314 | 86 |
| 2.0 | 170 | 2 × 100 = 200 | 200 | 30 | 340 | 60 |
| 2.2 | 187 | 2 × 100 = 200 | 200 | 13 | 374 | 26 |
| 2.4 | 204 | 1 × 200 + 1 × 50 = 250 | 250 | 46 | 408 | 92 |
Worked example — FOLFOX cycle billing for a 1.85 m² patient
# Step 1 — calculate dose
BSA: 1.85 m² × 85 mg/m² = 157.25 mg (round to 157 mg)
# Step 2 — vial selection
Two 100 mg vials drawn = 200 mg total
Administered: 157 mg · Waste: 43 mg
# Step 3 — convert mg to J9263 units (mg × 2)
Administered units (JZ line): 157 × 2 = 314 units
Waste units (JW line): 43 × 2 = 86 units
# Step 4 — admin coding for 2-hr infusion
Hour 1 (initial):
Hour 2 (each addl):
# Drug reimbursement (Q2 2026 ASP+6%)
Drug paid (administered + waste): 400 units × ~$0.078 = ~$31.20
# Note: admin codes generate substantially more revenue than the drug itself.
BSA: 1.85 m² × 85 mg/m² = 157.25 mg (round to 157 mg)
# Step 2 — vial selection
Two 100 mg vials drawn = 200 mg total
Administered: 157 mg · Waste: 43 mg
# Step 3 — convert mg to J9263 units (mg × 2)
Administered units (JZ line): 157 × 2 = 314 units
Waste units (JW line): 43 × 2 = 86 units
# Step 4 — admin coding for 2-hr infusion
Hour 1 (initial):
96413 × 1Hour 2 (each addl):
96415 × 1# Drug reimbursement (Q2 2026 ASP+6%)
Drug paid (administered + waste): 400 units × ~$0.078 = ~$31.20
# Note: admin codes generate substantially more revenue than the drug itself.
Adjuvant stage III colon cancer cycles
- FOLFOX schedule: 12 cycles over 6 months (q14d)
- Many patients require dose reduction or oxaliplatin discontinuation by cycle 8–10 due to cumulative neuropathy
- Consider 3-month adjuvant FOLFOX (6 cycles) for low-risk T3N1 disease per IDEA collaboration data
Solvent: D5W only, NOT saline
Oxaliplatin must be diluted in 5% Dextrose (D5W), NEVER 0.9% NaCl or any chloride-containing
solution. Chloride degrades oxaliplatin. Pharmacy compounding error here causes loss of drug
activity. Verify infusion bag selection and document if a saline-flush bracket is used.
NDC reference (representative generics) FDA NDC Directory verified May 2026
Multiple manufacturers; submit the actual NDC of the vial used. These are common examples.
| Manufacturer | NDC (10/11-digit) | Vial size | Notes |
|---|---|---|---|
| Hospira / Pfizer | 0409-0299-10 / 00409-0299-10 |
50 mg / 10 mL | 5 mg/mL preservative-free SDV |
| Hospira / Pfizer | 0409-0299-20 / 00409-0299-20 |
100 mg / 20 mL | Most commonly drawn for FOLFOX 85 mg/m² doses |
| Hospira / Pfizer | 0409-0299-40 / 00409-0299-40 |
200 mg / 40 mL | Used for high-BSA patients and CapeOx 130 mg/m² doses |
| Sandoz | 0781-3046-94 / 00781-3046-94 |
100 mg / 20 mL | Generic alternative |
| Accord Healthcare | 16729-243-66 / 16729-0243-66 |
100 mg / 20 mL | Generic alternative |
| Sanofi-Aventis (originator Eloxatin) | 0024-0590-50 / 00024-0590-50 |
50 mg / 10 mL | Originator brand — rarely seen post-generic |
Use the actual NDC of the vial drawn. Generic manufacturers carry different NDCs but all
bill under HCPCS J9263. If your buy-and-bill inventory rotates between Hospira, Sandoz, and Accord, your
billing system should pull the NDC from the lot used at admin time. NDC mismatch is a common
documentation deficiency in payer audits.
Phase 2
Code the claim
2-hour infusion needs both 96413 and 96415. Both JZ + JW required for BSA waste.
Administration codes CPT verified May 2026
Oxaliplatin is true cytotoxic chemotherapy — chemo admin codes are required.
| Code | Description | When to use |
|---|---|---|
96413 |
Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug | Hour 1 of oxaliplatin infusion (always primary). One unit per encounter as the initial drug. |
96415 |
Chemotherapy administration, IV infusion; each additional hour | Hour 2 of oxaliplatin (always × 1 unit). Standard infusion is 2 hours total. |
96417 |
Chemotherapy administration, IV infusion technique; each additional sequential infusion (different substance/drug) | For each subsequent agent in the FOLFOX/FOLFIRINOX/FLOT cycle (irinotecan, leucovorin, 5-FU bolus, docetaxel) |
96416 |
Initiation of prolonged chemotherapy infusion (more than 8 hours) requiring portable or implantable pump | For 5-FU 46-hour continuous infusion via take-home portable pump (FOLFOX/FOLFOXIRI/FOLFIRINOX/FLOT) |
96521 |
Refilling and maintenance of portable pump | For 46-hr 5-FU pump return/disconnect visit (Day 3) |
96365 / 96366 |
Therapeutic IV infusion (non-chemo) | NOT appropriate. Oxaliplatin is true cytotoxic chemotherapy — chemo admin codes apply. |
Why 2-hour infusion matters. Standard oxaliplatin infusion duration is 2 hours per the
FDA label. Slower infusion (4–6 hours) reduces acute cold-triggered peripheral neuropathy and
laryngopharyngeal spasm and may be ordered for patients with significant prior reactions. Faster
infusion (under 1 hour) is associated with worse acute neurotoxicity and is not recommended. Document
actual infusion time in the medical record — payers occasionally audit 96415 use against
documented chair time.
Modifiers — both JZ and JW required CMS verified May 2026
Why both JZ + JW for oxaliplatin (vs JZ-only for fixed-dose biologics)
Oxaliplatin is dosed by BSA (mg/m²) and supplied in fixed 50/100/200 mg vials — so the prepared dose almost never matches the vial sum exactly. Example: 1.85 m² patient needs 157 mg but the smallest vial combination drawn is 200 mg (two 100 mg vials). 43 mg is discarded. Bill the administered units under JZ and the discarded units under JW on a separate claim line. One of JZ or JW must be on every J9263 claim per CMS's July 2023 single-dose container policy — in practice oxaliplatin claims need BOTH.
| Modifier | Use | Example |
|---|---|---|
JZ |
Reports zero discarded drug from a single-dose container. Use on the line for administered units. | 1.85 m² FOLFOX dose: 314 units of J9263 with JZ (the 157 mg administered) |
JW |
Reports the discarded portion of a single-dose vial when waste exists. Use on a separate claim line for the wasted units. | Same dose: 86 units of J9263 with JW (the 43 mg discarded) |
25 (E/M) |
Significant separately identifiable E/M same day as infusion | Use on the E/M line, not on J9263. Routine pre-infusion clinical assessment is bundled. |
JG / TB |
340B-acquired drug modifiers per MAC policy | Required if facility participates in 340B and oxaliplatin is 340B-purchased. Verify per MAC. |
Common error: billing only JZ on a BSA-dosed claim with no JW line. Auditors flag this as
"implausible — whole-vial waste expected for BSA dosing with fixed vial sizes." Conversely, billing
both JZ and JW where total units exceed the vials drawn (e.g., bilingual JZ for 314 + JW for 86 should
equal exactly the vials drawn × 2 = 400 units). Reconcile JZ + JW units = vials drawn × 2.
JW reimbursement is real money on oxaliplatin. Wasted drug is reimbursable when documented
with JW. On a generic agent at ~$0.078/unit the absolute dollars per claim are modest, but at scale (100+
patients on adjuvant FOLFOX = 1,200 cycles/year), missed JW lines compound into meaningful underpayment.
ICD-10-CM by indication FY2026 verified May 2026
Oxaliplatin is on-label for colorectal, gastric/esophageal, and pancreatic cancers. Use the most specific code supported by encounter documentation.
| Indication | ICD-10 family | Notes |
|---|---|---|
| Colon cancer (by site) | C18.0–C18.9 | Most common: C18.7 (sigmoid), C18.2 (ascending), C18.3 (hepatic flexure), etc. |
| Rectosigmoid junction | C19 | Adjuvant + metastatic |
| Rectal cancer | C20 | Adjuvant + metastatic; total neoadjuvant therapy (TNT) increasingly common |
| Anal canal | C21.x | Off-label for anal SCC; FOLFOX has limited use |
| Pancreatic adenocarcinoma | C25.0–C25.9 | FOLFIRINOX: 1L metastatic + adjuvant |
| Gastric (stomach) | C16.0–C16.9 | FLOT peri-operative; FOLFOX 1L metastatic |
| Esophageal | C15.3–C15.9 | FLOT peri-operative for adenocarcinoma; FOLFOX off-label use |
| GE junction | C16.0 | FLOT or FOLFOX |
| Hepatocellular carcinoma | C22.0 | Off-label; FOLFOX has activity in some Asian guideline pathways |
| Biliary tract / cholangiocarcinoma | C22.1, C24.x | Off-label; gem/cis preferred but FOLFOX used in 2L |
| Drug-induced peripheral neuropathy | G62.0 | Use to support neuropathy management visits and dose-reduction documentation |
| Anaphylactic reaction (hx) | T80.52XA | For documenting prior infusion reaction; supports desensitization claims |
| Personal hx of malignant neoplasm | Z85.038 (colon), Z85.118 (other), etc. | For surveillance/follow-up after adjuvant FOLFOX completion |
Stage-specific PA documentation: for adjuvant FOLFOX, payers expect stage III (T any, N1–N2, M0) documentation with surgical pathology report. FOLFOX is generally not approved for stage I or stage II low-risk disease without high-risk features (T4, perforation, fewer than 12 nodes sampled, lymphovascular invasion).
Site of care & place of service Verified May 2026
Oxaliplatin is administered in physician oncology offices, hospital outpatient infusion centers, and ambulatory infusion suites. The 5-FU 46-hour CIV portable pump component (FOLFOX/FOLFIRINOX/FLOT) means patients leave the chair after the oxaliplatin + leucovorin + 5-FU bolus is complete (~3–4 hours chair time) and return on Day 3 for pump disconnect.
| Setting | POS | Claim form | Payer steering |
|---|---|---|---|
| Physician oncology office | 11 | CMS-1500 / 837P | Preferred by commercial UM |
| Ambulatory infusion suite (AIC) | 49 | CMS-1500 / 837P | Preferred by commercial UM |
| Oncology ASC | 24 | CMS-1500 / 837P | Acceptable |
| Hospital outpatient (on-campus) | 22 | UB-04 / 837I | Disfavored after first 3 months by major commercial plans |
| Hospital outpatient (off-campus PBD) | 19 | UB-04 / 837I | Disfavored after first 3 months by major commercial plans |
| Patient home (5-FU pump only) | 12 | n/a (pump return is in-office) | Pump itself is at home; oxaliplatin always in-office |
Anaphylaxis risk drives site-of-care policy. Even commercial UM that aggressively steers
biologics out of HOPD generally accepts in-office or AIC oxaliplatin administration because of the boxed
warning + cumulative anaphylaxis risk requiring resuscitation capacity. Home oxaliplatin is not done.
Claim form field mapping Verified May 2026
CMS-1500 / 837P fields for an oxaliplatin FOLFOX cycle.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering oncologist |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + actual lot NDC + ML + total volume drawn (e.g., 40 mL for two 100 mg vials) |
| HCPCS J9263 + JZ (administered units) | 24D (drug line 1) | Units = administered mg × 2 |
| HCPCS J9263 + JW (waste units) | 24D (drug line 2 — separate line) | Units = discarded mg × 2 |
| Drug units (administered) | 24G line 1 | e.g., 314 for 157 mg |
| Drug units (waste) | 24G line 2 | e.g., 86 for 43 mg |
| CPT 96413 (admin, hour 1) | 24D admin line A | One unit, oxaliplatin as initial drug |
| CPT 96415 (admin, addl hour) | 24D admin line B | One unit for hour 2 of oxaliplatin |
| CPT 96417 (each addl sequential) | 24D admin lines C+ | One per subsequent agent (irinotecan, 5-FU bolus, etc.) |
| CPT 96416 (initiation prolonged pump) | 24D admin line | For 5-FU 46-hr CIV via take-home pump |
| ICD-10 | 21 | Indication-specific (see ICD-10 table) |
| PA number | 23 | Most commercial payers; Medicare LCDs cover FDA + NCCN |
Phase 3
Get paid
Generic oxaliplatin is not the PA bottleneck. The combo agents (bevacizumab, cetuximab, pembrolizumab) are.
Payer policy snapshot Reviewed May 2026
| Payer | PA (oxaliplatin alone)? | Concurrent PA on combo agents? | Notes |
|---|---|---|---|
| Medicare (MAC LCDs) | No (covered for FDA + NCCN-recommended uses) | n/a | NCD/LCD framework covers oxaliplatin per FDA label + NCCN guidelines (off-label use compendium-supported) |
| UnitedHealthcare | Yes (oncology medical drug policy) | Yes — PA on bevacizumab, cetuximab, panitumumab, pembrolizumab combos | Aggressive site-of-care UM via Optum-managed program for HOPD; oxaliplatin itself rarely denied for on-label CRC/gastric/pancreatic |
| Aetna | Yes (CPB + Medical Drug policy) | Yes | Site-of-care steering after first 3 months for combo regimens involving biologics |
| BCBS plans | Generally no for oxaliplatin alone; varies by plan | Yes for combo biologics | Generally aligned with NCCN guidelines + FDA label |
Step therapy
Generally NOT required for oxaliplatin in FDA-labeled indications. Some payers require prior 5-FU/leucovorin failure before FOLFIRINOX in pancreatic cancer when patient performance status is marginal. Verify per-payer.
The PA fight is rarely about oxaliplatin itself. Generic oxaliplatin is cheap and on-label
for high-volume GI cancers. The PA friction comes from the combo biologics (bevacizumab, cetuximab,
pembrolizumab) where biomarkers (KRAS/NRAS/BRAF, MSI-H/dMMR) and line of therapy drive approval. Schedule
biomarker testing FIRST for any patient who may go on FOLFOX + EGFR antibody or FOLFOX + checkpoint
inhibitor.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — J9263
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions
ASP + 6%
$0.078
per 0.5 mg unit
170 mg FOLFOX dose
$26.52
340 units × ASP+6%
260 mg CapeOx dose
$40.56
520 units × ASP+6%
Annualized adjuvant FOLFOX drug cost: 12 cycles × ~$26.52/cycle (1.85 m² patient)
= ~$318/year in oxaliplatin acquisition cost. Among the lowest annualized drug costs of
any cytotoxic regimen because oxaliplatin has been generic since 2009. The administration codes
(96413 + 96415 + 96417 × sequential agents + 96416 for the 5-FU pump) generate substantially more
revenue than the oxaliplatin itself.
Coverage
No NCD specific to oxaliplatin. Coverage falls under MAC LCDs for chemotherapy + the generic drug-coverage framework. All MACs cover J9263 for FDA-approved on-label indications (CRC, gastric, pancreatic) and NCCN-compendium-supported off-label uses with appropriate ICD-10 documentation.
Code history
- J9263 — "Injection, oxaliplatin, 0.5 mg" (permanent)
- 0.5 mg unit basis is unusual for the platinum class — carboplatin J9045 is per 50 mg, cisplatin J9060 is per 1 mg. Oxaliplatin's 0.5 mg basis is the most common biller error on the code.
Platinum class comparison
| Drug | HCPCS | Unit basis | Generation | Primary indications | Hallmark toxicity |
|---|---|---|---|---|---|
| Oxaliplatin | J9263 |
0.5 mg | 3rd gen | Colorectal, gastric, pancreatic (FOLFOX, FOLFIRINOX, FLOT) | Peripheral neuropathy (acute cold-triggered + chronic cumulative); anaphylaxis (boxed) |
| Carboplatin | J9045 |
50 mg | 2nd gen | Ovarian, lung, breast, head & neck | Myelosuppression (esp. thrombocytopenia); less neurotoxic than cisplatin |
| Cisplatin | J9060 |
1 mg | 1st gen | Multiple solid tumors (testicular, bladder, lung, head & neck) | Nephrotoxicity (requires hydration), ototoxicity, severe nausea, neuropathy |
Class context: Oxaliplatin is the preferred platinum for GI malignancies because it's
active where carboplatin and cisplatin are not (notably colon cancer). Cisplatin and carboplatin retain
primacy in gynecologic, lung, and head & neck cancers. The three platinums are not interchangeable
— substituting one for another is regimen-defining, not cosmetic.
Patient assistance Verified May 2026
- Generic manufacturer support: Hospira/Pfizer, Sandoz, and Accord all run generic oncology product assistance programs — verify with the dispensing pharmacy at the time of buy-and-bill purchase
- Sanofi Patient Connection: 1-888-847-4877 / sanofipatientconnection.com — legacy Eloxatin support program; covers brand Eloxatin only (rarely seen post-generic)
- Foundations (oncology): PAN Foundation, HealthWell Foundation, CancerCare Co-Payment Assistance Foundation — verify open colorectal, gastric, and pancreatic cancer funds quarterly
- Co-Pay Relief (PAF): Patient Advocate Foundation — co-pay assistance for chemotherapy patients
- NeedyMeds: needymeds.org — aggregator of patient assistance programs across generic chemo agents
Generic oxaliplatin is rarely the OOP burden. Patient cost concerns on FOLFOX/CapeOx
regimens typically come from the combo biologics (bevacizumab, cetuximab, pembrolizumab) and the
infusion administration coinsurance (Medicare Part B 20%). Run a CareCost Estimate to see total cycle
OOP including all drugs, admin, premedications, and supportive care —
J9263 pre-loaded.
Phase 4
Safety, warnings & denials
Anaphylaxis is the boxed warning. Peripheral neuropathy is the dose-limiting toxicity.
Boxed warning — anaphylaxis FDA label verified May 2026
BOXED WARNING: Severe hypersensitivity / anaphylactic reactions to oxaliplatin can occur
within minutes of infusion start. Symptoms include facial flushing, generalized urticaria, dyspnea,
bronchospasm, hypotension, and cardiovascular collapse. Healthcare professional administration only.
Epinephrine, corticosteroids, antihistamines, and resuscitation equipment must be immediately available.
Discontinue oxaliplatin if anaphylaxis is confirmed.
Risk pattern
- Most reactions occur after multiple cycles (cumulative sensitization)
- Highest risk window: cycles 7–12 of FOLFOX
- Cross-reactivity with other platinums (cisplatin, carboplatin) is real — document any prior platinum reaction history
- Re-treatment after anaphylaxis requires desensitization protocol via specialty oncology pharmacy — rare
Documentation that supports billing
- Premedication ordered per protocol (5-HT3 antagonist + dexamethasone + NK1 RA standard; antihistamine added if prior reaction)
- Vital signs at baseline, 15 min, 30 min, 1 hr, 2 hr (end of infusion)
- Resuscitation equipment availability documented
- If reaction occurs: T80.52XA (anaphylactic reaction due to therapeutic drug, initial encounter); for subsequent monitoring use T80.52XD
- Discontinuation note in oncologist's record if oxaliplatin is dropped
Other important warnings & precautions (not boxed)
- Myelosuppression — thrombocytopenia, neutropenia, anemia; CBC required prior to each cycle
- Pulmonary fibrosis / interstitial lung disease — rare but serious; investigate new dyspnea
- Hepatotoxicity — sinusoidal obstruction syndrome (SOS) with prolonged use; monitor LFTs
- Posterior reversible encephalopathy syndrome (PRES) — rare; evaluate any new seizure or visual disturbance
- QT prolongation — rare; baseline ECG advisable in patients with cardiac history
- Embryo-fetal toxicity — effective contraception required during and 9 months after therapy (females), 6 months (males)
Peripheral neuropathy — the dose-limiting toxicity FDA label + NCCN verified May 2026
Oxaliplatin causes two distinct peripheral neuropathy syndromes. Coders should distinguish them in clinical notes for support documentation, and patients require explicit education about cold avoidance.
| Acute (cold-triggered) | Chronic (cumulative) | |
|---|---|---|
| Incidence | 85–95% of patients | ~50% at >12 cycles |
| Onset | During or within hours of infusion | Cumulative over multiple cycles, peaks 6–12 cycles in |
| Trigger | Cold exposure (cold drinks, cold air, ice, metal door handles) | Cumulative dose; not cold-triggered |
| Symptoms | Paresthesia, dysesthesia in hands/feet/perioral; pharyngolaryngeal dysesthesia (sense of inability to breathe) | Persistent numbness, tingling, loss of fine motor control, gait instability |
| Reversibility | Usually resolves between cycles | May be permanent; partial recovery over months to years |
| Management | Cold avoidance education; warm gloves/scarves; slower infusion (4–6 hr) if severe | Hold or reduce dose if Grade 2+; "stop-and-go" oxaliplatin holiday after 6 cycles in mCRC; discontinue if Grade 3+ |
| ICD-10 | G62.0 drug-induced polyneuropathy | G62.0 |
Patient cold-avoidance education is critical and bills under E/M (not as a separate procedure).
Patients must avoid cold drinks (use straws, room-temp), cold air (scarves over face in winter), ice
(ice packs, ice cubes), and cold metal (gloves to open refrigerator). Education at cycle 1 is part of
the infusion encounter; reinforce at every cycle. Document the patient's adherence and any new symptoms.
Stop-and-go strategy in mCRC: per OPTIMOX studies and NCCN guidelines, planned
oxaliplatin discontinuation after 6 cycles of FOLFOX in metastatic CRC (continuing 5-FU/leucovorin
maintenance) reduces chronic neuropathy without compromising efficacy, with reintroduction at progression.
Document the stop-and-go plan in the oncologist's note for adjudication of any payer questions about
regimen modification.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Underpayment / units flagged as low | Billed J9263 in mg, not 0.5 mg units | Convert administered mg × 2 for units. Resubmit corrected claim. This is the #1 oxaliplatin error. |
| JW missing on BSA-dosed claim | Wasted drug not reported separately | Add a separate J9263 line with JW + waste units. CMS audit pattern: BSA dosing without JW = implausible. |
| Wrong admin code (96365) | Therapeutic IV billed instead of chemo IV | Resubmit with 96413 + 96415. Oxaliplatin is true cytotoxic chemo. |
| Missing 96415 for hour 2 | Only 96413 billed for full 2-hr infusion | Add 96415 × 1 unit for hour 2. Documented chair time supports the claim. |
| NDC mismatch on lot | Billed Hospira NDC but Sandoz or Accord lot dispensed | Pull NDC from actual lot at admin time. Generic interchange happens at the buy-and-bill level. |
| Stage / line of therapy not documented | Adjuvant FOLFOX submitted without stage III pathology | Submit surgical pathology report showing stage III (T any, N1-N2, M0) or high-risk stage II features. |
| Sequential infusion codes missing | FOLFOX cycle billed with only 96413 + 96415 (no 96417 for subsequent agents) | Add 96417 × 1 for each additional agent (irinotecan, 5-FU bolus, leucovorin if separate). Add 96416 for 5-FU 46-hr pump. |
| Combo biologic PA missing | FOLFOX approved but bevacizumab/cetuximab/pembrolizumab not | Submit separate PA for each combo agent. Bevacizumab requires no biomarker; cetuximab/panitumumab require KRAS/NRAS/BRAF testing; pembrolizumab requires MSI-H/dMMR. |
| Solvent error documentation | Pharmacy used saline instead of D5W | This is a pharmacy compounding error, not a billing error — drug is degraded; do not administer; document waste; may not be reimbursable. |
Frequently asked questions
What is the HCPCS code for oxaliplatin?
Oxaliplatin (Eloxatin originator + all generics) is billed under HCPCS J9263 —
"Injection, oxaliplatin, 0.5 mg." 1 unit = 0.5 mg, not 1 mg. This is unusual among
platinum chemo agents and is the single most common biller error on the code.
How many units do I bill for an 85 mg/m² FOLFOX dose?
Multiply the patient's BSA by 85 to get total mg, then double that number for J9263 units. Examples: 1.7 m² = 145 mg = 290 units; 1.85 m² = 157 mg = 314 units; 2.0 m² = 170 mg = 340 units; 2.2 m² = 187 mg = 374 units.
What administration CPT do I use for oxaliplatin?
CPT 96413 for hour 1 + CPT 96415 × 1 for hour 2. Standard infusion is
2 hours per the FDA label; slower infusion reduces acute peripheral neuropathy. For combination
regimens, oxaliplatin is the initial drug; subsequent agents bill 96417 (each additional
sequential infusion). 5-FU 46-hr CIV via portable pump bills 96416. Do NOT bill
96365.
Do I bill JZ or JW for oxaliplatin?
Both, on virtually every claim. Oxaliplatin is BSA-dosed but vials are fixed at 50/100/200 mg, so partial-vial waste is the norm. Bill JZ on the line for administered units and JW on a separate line for waste units. Both lines convert mg → units by × 2. CMS requires JZ or JW on every single-dose container claim per the July 2023 policy.
What is the Medicare reimbursement for J9263?
For Q2 2026, the Medicare Part B payment limit for J9263 is approximately $0.078 per 0.5 mg unit (ASP + 6%). A 170 mg FOLFOX dose (340 units) costs about $26.52; a 260 mg CapeOx dose (520 units) about $40.56. Annualized adjuvant FOLFOX drug cost: ~$318/year. Among the lowest cytotoxic per-mg costs because the drug has been generic since 2009.
Which combination regimens use oxaliplatin?
Five major NCCN regimens: FOLFOX (1L mCRC + adjuvant CRC, 85 mg/m² q14d), FOLFOXIRI (more aggressive 1L mCRC, 85 mg/m² q14d), CapeOx / XELOX (1L mCRC alternative + adjuvant CRC, 130 mg/m² q21d), FOLFIRINOX (pancreatic, 85 mg/m² q14d), FLOT (peri-operative gastric/esophageal, 85 mg/m² q14d). FOLFOX is the workhorse and accounts for the majority of oxaliplatin claim volume.
What is the boxed warning for oxaliplatin?
Anaphylaxis. Severe hypersensitivity reactions (facial flushing, dyspnea, bronchospasm, hypotension, cardiovascular collapse) can occur within minutes of infusion start. Risk increases with cumulative cycles — highest risk at cycles 7–12. Healthcare professional administration only with epinephrine and resuscitation equipment immediately available. Discontinue if anaphylaxis confirmed.
What are oxaliplatin's two peripheral neuropathy patterns?
(1) Acute cold-triggered (85–95% of patients): paresthesia, dysesthesia in
extremities and perioral region, triggered by cold exposure. Usually resolves between cycles. Patient
education to avoid cold (drinks, air, ice, metal) is essential. (2) Chronic cumulative
(~50% at >12 cycles): persistent peripheral neuropathy that may be permanent; this is the dose-limiting
toxicity. Consider holding or reducing oxaliplatin if Grade 2+, discontinue if Grade 3+. ICD-10
G62.0 (drug-induced polyneuropathy) supports neuropathy management claims.
Why must oxaliplatin be diluted in D5W and not saline?
Chloride degrades oxaliplatin. The drug must be diluted in 5% Dextrose (D5W) only — never in 0.9% NaCl or any chloride-containing solution. Pharmacy compounding errors here cause loss of drug activity. Verify infusion bag selection at pharmacy and document the diluent in the medical record.
How is oxaliplatin different from carboplatin and cisplatin?
All three are platinum-based DNA-crosslinking cytotoxics, but they're not interchangeable. Oxaliplatin (J9263, 3rd gen) is the platinum for GI cancers (CRC, gastric, pancreatic); peripheral neuropathy is the hallmark toxicity. Carboplatin (J9045, 2nd gen) is used in ovarian, lung, breast, and head & neck cancers; myelosuppression (especially thrombocytopenia) is the hallmark toxicity. Cisplatin (J9060, 1st gen) is used across many solid tumors; nephrotoxicity (requires aggressive hydration) is the hallmark. Substituting one platinum for another is regimen-defining, not cosmetic.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- DailyMed — Oxaliplatin (Eloxatin originator + multiple generic SPLs)
- FDA Eloxatin label PDF (s015, 2015)
- CMS — Medicare Part B Drug ASP Pricing File
- SEER CanMED — HCPCS J9263 reference
- NCCN Clinical Practice Guidelines in Oncology — Colon Cancer (v.2.2026)
- NCCN Clinical Practice Guidelines — Rectal Cancer (v.2.2026)
- NCCN Clinical Practice Guidelines — Pancreatic Adenocarcinoma (v.2.2026)
- NCCN Clinical Practice Guidelines — Gastric Cancer (v.2.2026)
- UnitedHealthcare — Oncology Medication Clinical Coverage Policy
- Aetna CPB — Colorectal Cancer Chemotherapy
- FDA National Drug Code Directory
- Sanofi Patient Connection (legacy Eloxatin support)
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Payer policies (UHC, Aetna, BCBS) | Semi-annual | Manual review against published payer policy documents. |
| NCCN regimens (FOLFOX, FOLFIRINOX, FLOT) | Semi-annual | Reviewed against NCCN CRC + Gastric + Pancreatic guideline updates. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases. |
| NDC, dosing, FDA label | Event-driven | Tied to FDA label revision date and generic NDC additions/withdrawals. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA label, CMS,
NCCN guidelines, payer policy documents — all linked above). Editorial review in progress. Until that review is complete, treat this as a draft reference and verify
each cited source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026. NCCN: v.2.2026 CRC + Gastric + Pancreatic. FDA label: Eloxatin originator + generic SPLs. Five combo regimens documented (FOLFOX, FOLFOXIRI, CapeOx, FOLFIRINOX, FLOT). Boxed warning anaphylaxis + peripheral neuropathy two-pattern callouts included. Platinum class comparison vs carboplatin (J9045) and cisplatin (J9060).
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Combo regimens are verified against NCCN guideline current version. We do not paraphrase from billing-software vendor blogs.